Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 474 shares, an increase of 169.3% from the July 15th total of 176 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is presently ∞ days. Approximately 0.0% of the shares of the company are short sold.
Basilea Pharmaceutica Price Performance
BPMUF stock opened at $65.50 on Friday. Basilea Pharmaceutica has a 12 month low of $59.29 and a 12 month high of $74.00. The company has a quick ratio of 4.68, a current ratio of 5.11 and a debt-to-equity ratio of 0.59. The firm’s fifty day simple moving average is $61.46 and its 200-day simple moving average is $66.83.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Further Reading
- Five stocks we like better than Basilea Pharmaceutica
- Asian Market Circuit Breakers Hit Stocks, Not AI Demand
- Riot Platforms Re-Wires the Ledger for a $9B AI Power Play
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
